Therapeutic vaccines in renal cell carcinoma. Issue 4 (July 2011)

• Record Type: Journal Article
• Authors: Schwaab, Thomas; Ernstoff, Marc S
• Is Part Of: Therapy. Volume 8:Issue 4(2011)
• Page Start: 369
• Page End: 377
• Publication Date: 2011-07
• Subjects: dendritic cells -- immune therapy -- renal cell cancer -- T cells -- tumor vaccine; Therapeutics -- Periodicals; Chemotherapy -- Periodicals; 615.505
• DOI: 10.2217/thy.11.40
• Languages: English
• ISSNs: 1475-0708

Abstract

Metastatic renal cell carcinoma (mRCC) is a lethal disease. The advent of tyrosine kinase inhibitors (TKIs) has changed the disease process, yet the majority of patients will develop treatment-resistant disease. IL-2 based immunotherapy in mRCC is the only US FDA-approved treatment with curative results. Immunotherapeutic vaccine approaches to mRCC have been under investigation for several decades with mixed results. The recent FDA-approval of the first cellular immunotherapy in prostate cancer (Provenge ®® ) has reinvigorated the search for similar vaccines approaches in mRCC. This review introduces the concepts and different features required for a successful anticancer vaccine approach.